Travere Therapeutics Appoints Bradley Campbell as New CEO
Travere Therapeutics (TVTX) has announced the appointment of Bradley Campbell as its new chief executive officer, effective December 1, 2026. The company stated that Eric Dube will step down from his roles as CEO and president to focus on personal health matters. This leadership transition is expected to bring a fresh strategic direction under Campbell’s experience in the biopharmaceutical industry. While no immediate financial impact was disclosed, such executive changes can influence investor sentiment depending on market perception of the new leader's capabilities and vision for the company.
Tickers: $TVTX
Topics: CEO appointment Leadership change